Search - tctmd.com

Displaying 21 - 40 of 238

Sort: Relevancy | Date

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

News Conference News ACC 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

April 16, 2024

Evoque and Patisiran: A Tale of Two Regulatory Journeys

News Opinion Off Script

Evoque and Patisiran: A Tale of Two Regulatory Journeys

Sanjay Kaul, MD

March 29, 2024

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

News Daily News

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

Michael O'Riordan

March 20, 2024

BP Reductions Last 5 Years After Bariatric Surgery: GATEWAY

News Daily News

BP Reductions Last 5 Years After Bariatric Surgery: GATEWAY

Michael O'Riordan

February 07, 2024

Slash Dietary Sodium, Slash Blood Pressure: CARDIA-SSBP

News Conference News AHA 2023

Slash Dietary Sodium, Slash Blood Pressure: CARDIA-SSBP

Michael O'Riordan

November 12, 2023

RDN to treat Resistant Hypertension

Presentation

RDN to treat Resistant Hypertension

Presenter: Tai Kobayashi

November 10, 2023

FDA Approves Paradise Renal Denervation System: What Comes Next?

News Daily News

FDA Approves Paradise Renal Denervation System: What Comes Next?

November 08, 2023

RADIANCE Modest Renal Denervation Effect Remains at 6 Months

News Conference News TCT 2023

RADIANCE: 'Modest' Renal Denervation Effect Remains at 6 Months

October 31, 2023

TCT 726: Efficacy of Renal Denervation and antihypertensives in patients with resistant hypertension: A systematic review and Network meta analysis

Presentation TCT 2023

TCT 726: Efficacy of Renal Denervation and antihypertensives in patients with resistant hypertension: A systematic review and Network meta analysis

Presenter: Hamza Naveed

October 25, 2023

TCT 210: Long-term Safety and Efficacy of Endovascular Ultrasound Renal Denervation in Resistant Hypertension: 8-year results from the ACHIEVE study

Presentation TCT 2023

TCT 210: Long-term Safety and Efficacy of Endovascular Ultrasound Renal Denervation in Resistant Hypertension: 8-year results from the ACHIEVE study

Presenter: Victor Zeijen

October 25, 2023

TCT 152: Echocardiographic Findings Following Renal Sympathetic denervationfor treatment resistant hypertension, The ReShape CV-risk study.

Presentation TCT 2023

TCT 152: Echocardiographic Findings Following Renal Sympathetic denervationfor treatment resistant hypertension, The ReShape CV-risk study.

Presenter: Anna Subbotina

October 25, 2023

ReCor’s Renal Denervation System Gets Thumbs Up From FDA Advisory Panel

News Daily News

ReCor’s Renal Denervation System Gets Thumbs Up From FDA Advisory Panel

August 22, 2023

As Renal Denervation Heads to Advisory Review, FDA Sets Out Key Questions

News Daily News

As Renal Denervation Heads to Advisory Review, FDA Sets Out Key Questions

August 18, 2023

Over Decades, Women Still Missing in NIH-Funded Trials for CVD

News Daily News

Over Decades, Women Still Missing in NIH-Funded Trials for CVD

June 30, 2023

Loop Diuretics Are Heavily Prescribed Outside of HF: That’s a Problem

News Conference News ESC Heart Failure 2023

Loop Diuretics Are Heavily Prescribed Outside of HF: That’s a Problem

May 23, 2023

Renal Denervation: Exploring Its Potential Beyond Hypertension

News Conference News EuroPCR 2023

Renal Denervation: Exploring Its Potential Beyond Hypertension

May 18, 2023

HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension

News Conference News ACC 2023

HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension

March 08, 2023

BP Reduction With Renal Denervation Still Evident a Decade On

News Daily News

BP Reduction With Renal Denervation Still Evident a Decade On

Michael O'Riordan

January 31, 2023

Novel Aldosterone Synthase Inhibitor Drops BP: Top-line Phase II Results

News Daily News

Novel Aldosterone Synthase Inhibitor Drops BP: Top-line Phase II Results

November 16, 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

News Conference News AHA 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

Michael O'Riordan

November 09, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.